{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:01:17Z","timestamp":1789830077807,"version":"4.0.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020297","name":"Abiomed","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020297","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40119-025-00441-5","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T09:38:21Z","timestamp":1765618701000},"page":"25-42","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impella vs. IABP in Non-emergent High-Risk PCI: Outcomes and LVEF Recovery from a Large US EHR Study"],"prefix":"10.1007","volume":"15","author":[{"given":"Jason R.","family":"Wollmuth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya S.","family":"Bharadwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nudrat","family":"Noor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Almedhychy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,13]]},"reference":[{"key":"441_CR1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.115.003405","volume":"8","author":"TA Bass","year":"2015","unstructured":"Bass TA. High-risk percutaneous coronary interventions in modern day clinical practice: current concepts and challenges. Circ Cardiovasc Interv. 2015;8:e003405. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.115.003405.","journal-title":"Circ Cardiovasc Interv"},{"key":"441_CR2","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.cjca.2024.01.003","volume":"40","author":"W Shamkhani","year":"2024","unstructured":"Shamkhani W, Rashid M, Moledina S, et al. Complex high-risk percutaneous coronary intervention types, trends, and outcomes in nonsurgical centres. Can J Cardiol. 2024;40:1237\u201346. https:\/\/doi.org\/10.1016\/j.cjca.2024.01.003.","journal-title":"Can J Cardiol"},{"key":"441_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.872398","author":"A Achim","year":"2022","unstructured":"Achim A, Marc M, Ruzsa Z. Surgical turned-downed CHIP cases\u2014can PCI save the day? Front Cardiovasc Med. 2022. https:\/\/doi.org\/10.3389\/fcvm.2022.872398.","journal-title":"Front Cardiovasc Med"},{"key":"441_CR4","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.015317","author":"A Kataruka","year":"2020","unstructured":"Kataruka A, Maynard CC, Kearney KE, et al. Temporal trends in percutaneous coronary intervention and coronary artery bypass grafting: insights from the Washington Cardiac Care Outcomes Assessment Program. J Am Heart Assoc. 2020. https:\/\/doi.org\/10.1161\/JAHA.119.015317.","journal-title":"J Am Heart Assoc"},{"key":"441_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.amjcard.2024.04.042","volume":"222","author":"AS Bharadwaj","year":"2024","unstructured":"Bharadwaj AS, Truesdell AG, Lemor A, et al. Characteristics of patients undergoing high-risk percutaneous coronary intervention in contemporary United States practice. Am J Cardiol. 2024;222:8\u201310. https:\/\/doi.org\/10.1016\/j.amjcard.2024.04.042.","journal-title":"Am J Cardiol"},{"key":"441_CR6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.123.013503","volume":"17","author":"AS Bharadwaj","year":"2024","unstructured":"Bharadwaj AS, Abu-Much A, Maini AS, et al. Angiographic characteristics and clinical outcomes in patients with chronic kidney disease undergoing Impella-supported high-risk percutaneous coronary intervention: insights from the cVAD PROTECT\u00a0III study. Circ Cardiovasc Interv. 2024;17:e013503. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.123.013503.","journal-title":"Circ Cardiovasc Interv"},{"key":"441_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ahj.2022.02.006","volume":"248","author":"WW O\u2019Neill","year":"2022","unstructured":"O\u2019Neill WW, Anderson M, Burkhoff D, et al. Improved outcomes in patients with severely depressed LVEF undergoing percutaneous coronary intervention with contemporary practices. Am Heart J. 2022;248:139\u201349. https:\/\/doi.org\/10.1016\/j.ahj.2022.02.006.","journal-title":"Am Heart J"},{"key":"441_CR8","doi-asserted-by":"crossref","unstructured":"Falah B, Tehrani B, Thompson JB, et al. Short-term outcomes of impella-supported high-risk PCI in surgically ineligible patients: insights from PROTECT\u00a0III. J Soc Cardiovasc Angiogr Interv. 2025;4(10Part A):103859.","DOI":"10.1016\/j.jscai.2025.103859"},{"key":"441_CR9","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.3978\/j.issn.2072-1439.2015.10.57","volume":"7","author":"V Ganyukov","year":"2015","unstructured":"Ganyukov V, Tarasov R. High risk percutaneous coronary interventions-significance of left ventricular assist device for clinical practice. J Thorac Dis. 2015;7:1716\u20138. https:\/\/doi.org\/10.3978\/j.issn.2072-1439.2015.10.57.","journal-title":"J Thorac Dis"},{"key":"441_CR10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.120.009960","volume":"14","author":"N Khalid","year":"2021","unstructured":"Khalid N, Rogers T, Torguson R, et al. Feasibility and safety of high-risk percutaneous coronary intervention without mechanical circulatory support. Circ Cardiovasc Interv. 2021;14:E009960. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.120.009960.","journal-title":"Circ Cardiovasc Interv"},{"key":"441_CR11","doi-asserted-by":"publisher","first-page":"E135","DOI":"10.4244\/EIJ-D-23-00512","volume":"20","author":"S Min","year":"2024","unstructured":"Min S, Basir MB, Lemor A, et al. Clinical characteristics and outcomes of patients requiring prolonged mechanical circulatory support after high-risk percutaneous coronary intervention. EuroIntervention. 2024;20:E135\u201345. https:\/\/doi.org\/10.4244\/EIJ-D-23-00512.","journal-title":"EuroIntervention"},{"key":"441_CR12","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001038","author":"JS Lawton","year":"2022","unstructured":"Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022. https:\/\/doi.org\/10.1161\/CIR.0000000000001038.","journal-title":"Circulation"},{"key":"441_CR13","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45:3415\u2013537. https:\/\/doi.org\/10.1093\/eurheartj\/ehae177.","journal-title":"Eur Heart J"},{"key":"441_CR14","doi-asserted-by":"publisher","DOI":"10.4244\/EIJY21M05_01","author":"A Chieffo","year":"2021","unstructured":"Chieffo A, Dudek D, Hassager C, et al. Joint EAPCI\/ACVC expert consensus document on percutaneous ventricular assist devices. EuroIntervention. 2021. https:\/\/doi.org\/10.4244\/EIJY21M05_01.","journal-title":"EuroIntervention"},{"key":"441_CR15","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1161\/CIRCULATIONAHA","volume":"126","author":"WW O\u2019Neill","year":"2012","unstructured":"O\u2019Neill WW, Kleiman NS, Moses J, et al. A prospective, randomized clinical trial of hemodynamic support with Impella\u00a02.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT\u00a0II study. Circulation. 2012;126:1717\u201327. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.","journal-title":"Circulation"},{"key":"441_CR16","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.amjcard.2013.09.008","volume":"113","author":"GD Dangas","year":"2014","unstructured":"Dangas GD, Kini AS, Sharma SK, et al. Impact of hemodynamic support with impella 2.5 versus intra-aortic balloon pump on prognostically important clinical outcomes in patients undergoing high-risk percutaneous coronary intervention (from the PROTECT\u00a0II randomized trial). Am J Cardiol. 2014;113:222\u20138. https:\/\/doi.org\/10.1016\/j.amjcard.2013.09.008.","journal-title":"Am J Cardiol"},{"key":"441_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jscai.2022.100350","volume":"1","author":"J Wollmuth","year":"2022","unstructured":"Wollmuth J, Patel MP, Dahle T, et al. Ejection fraction improvement following contemporary high-risk percutaneous coronary intervention: RESTORE\u00a0EF study results. J Soc Cardiovasc Angiogr Interv. 2022;1:100350. https:\/\/doi.org\/10.1016\/j.jscai.2022.100350.","journal-title":"J Soc Cardiovasc Angiogr Interv"},{"key":"441_CR18","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jchf.2018.01.024","volume":"6","author":"D Perera","year":"2018","unstructured":"Perera D, Clayton T, Petrie MC, et al. Percutaneous revascularization for ischemic ventricular dysfunction: rationale and design of the REVIVED-BCIS2 trial: percutaneous coronary intervention for ischemic cardiomyopathy. JACC Heart Fail. 2018;6:517\u201326. https:\/\/doi.org\/10.1016\/j.jchf.2018.01.024.","journal-title":"JACC Heart Fail"},{"key":"441_CR19","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1056\/nejmoa2206606","volume":"387","author":"D Perera","year":"2022","unstructured":"Perera D, Clayton T, O\u2019Kane PD, et al. Percutaneous revascularization for ischemic left ventricular dysfunction. N Engl J Med. 2022;387:1351\u201360. https:\/\/doi.org\/10.1056\/nejmoa2206606.","journal-title":"N Engl J Med"},{"key":"441_CR20","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2217\/CER.13.65","volume":"2","author":"B Gallego","year":"2013","unstructured":"Gallego B, Dunn AG, Coiera E. Role of electronic health records in comparative effectiveness research. J Comp Eff Res. 2013;2:529\u201332. https:\/\/doi.org\/10.2217\/CER.13.65.","journal-title":"J Comp Eff Res"},{"issue":"1","key":"441_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-024-77535-Y","volume":"14","author":"MM Dagli","year":"2024","unstructured":"Dagli MM, Ghenbot Y, Ahmad HS, et al. Development and validation of a novel AI framework using NLP with LLM integration for relevant clinical data extraction through automated chart review. Sci Rep. 2024;14(1):26783. https:\/\/doi.org\/10.1038\/S41598-024-77535-Y.","journal-title":"Sci Rep"},{"key":"441_CR22","unstructured":"Truveta Machine Learning and Clinical Informatics Teams. Utilizing echocardiogram data in clinical notes: data extraction and validation. Truveta Guidance Document. 2025. https:\/\/www.truveta.com\/resources\/briefing\/normalizing-and-extracting-echocardiogram-data\/. Accessed 12 Oct 2025."},{"key":"441_CR23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.121.011284","volume":"15","author":"RS Velagaleti","year":"2022","unstructured":"Velagaleti RS, Vetter J, Parker R, et al. Change in left ventricular ejection fraction with coronary artery revascularization and subsequent risk for adverse cardiovascular outcomes. Circ Cardiovasc Interv. 2022;15:E011284. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.121.011284.","journal-title":"Circ Cardiovasc Interv"},{"key":"441_CR24","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/ccd.23403","volume":"80","author":"B Maini","year":"2012","unstructured":"Maini B, Naidu SS, Mulukutla S, et al. Real-world use of the Impella\u00a02.5 circulatory support system in complex high-risk percutaneous coronary intervention: the USpella registry. Catheter Cardiovasc Interv. 2012;80:717\u201325. https:\/\/doi.org\/10.1002\/ccd.23403.","journal-title":"Catheter Cardiovasc Interv"},{"key":"441_CR25","doi-asserted-by":"publisher","first-page":"E501","DOI":"10.1002\/ccd.29758","volume":"98","author":"BP O\u2019Neill","year":"2021","unstructured":"O\u2019Neill BP, Grines C, Moses JW, et al. Outcomes of bailout percutaneous ventricular assist device versus prophylactic strategy in patients undergoing nonemergent percutaneous coronary intervention. Catheter Cardiovasc Interv. 2021;98:E501\u201312. https:\/\/doi.org\/10.1002\/ccd.29758.","journal-title":"Catheter Cardiovasc Interv"},{"key":"441_CR26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ahj.2017.09.007","volume":"199","author":"GW Vetrovec","year":"2018","unstructured":"Vetrovec GW, Anderson M, Schreiber T, et al. The cVAD registry for percutaneous temporary hemodynamic support: a prospective registry of Impella mechanical circulatory support use in high-risk PCI, cardiogenic shock, and decompensated heart failure. Am Heart J. 2018;199:115\u201321. https:\/\/doi.org\/10.1016\/j.ahj.2017.09.007.","journal-title":"Am Heart J"},{"key":"441_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.amjcard.2022.08.032","volume":"185","author":"AJ Lansky","year":"2022","unstructured":"Lansky AJ, Tirziu D, Moses JW, et al. Impella versus intra-aortic balloon pump for high-risk PCI: a propensity-adjusted large-scale claims dataset analysis. Am J Cardiol. 2022;185:29\u201336. https:\/\/doi.org\/10.1016\/j.amjcard.2022.08.032.","journal-title":"Am J Cardiol"},{"key":"441_CR28","doi-asserted-by":"crossref","unstructured":"Elze MC, Gregson J, Baber U, et al. Comparison of propensity score methods and covariate adjustment evaluation in 4 cardiovascular studies.  J Am Coll Cardiol. 2017;69(3):345\u201357.","DOI":"10.1016\/j.jacc.2016.10.060"},{"key":"441_CR29","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.040167","author":"P Urban","year":"2019","unstructured":"Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation. 2019. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.040167.","journal-title":"Circulation"},{"key":"441_CR30","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jcin.2008.11.005","volume":"2","author":"SR Dixon","year":"2009","unstructured":"Dixon SR, Henriques JPS, Mauri L, et al. A prospective feasibility trial investigating the use of the Impella\u00a02.5 system in patients undergoing high-risk percutaneous coronary intervention (the PROTECT\u00a0I trial). Initial U.S. experience. JACC Cardiovasc Interv. 2009;2:91\u20136. https:\/\/doi.org\/10.1016\/j.jcin.2008.11.005.","journal-title":"JACC Cardiovasc Interv"},{"key":"441_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/5243913","volume":"2019","author":"F Burzotta","year":"2019","unstructured":"Burzotta F, Russo G, Ribichini F, et al. Long-term outcomes of extent of revascularization in complex high risk and indicated patients undergoing impella-protected percutaneous coronary intervention: report from the Roma-Verona Registry. J Interv Cardiol. 2019;2019:1\u201310. https:\/\/doi.org\/10.1155\/2019\/5243913.","journal-title":"J Interv Cardiol"},{"key":"441_CR32","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/ccd.31392","volume":"105","author":"I Gallo","year":"2025","unstructured":"Gallo I, Azzalini L, Gonz\u00e1lez-Manzanares R, et al. Mechanical circulatory support with Impella in high-risk patients with chronic total occlusion and complex multivessel disease. Catheter Cardiovasc Interv. 2025;105:883\u201390. https:\/\/doi.org\/10.1002\/ccd.31392.","journal-title":"Catheter Cardiovasc Interv"},{"key":"441_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2023.05.048","author":"E Romagnoli","year":"2023","unstructured":"Romagnoli E, Burzotta F, Cerracchio E, et al. Impact of Impella protected-percutaneous coronary intervention on left ventricle function recovery of patients with extensive coronary disease and poor left ventricular function. Int J Cardiol. 2023. https:\/\/doi.org\/10.1016\/j.ijcard.2023.05.048.","journal-title":"Int J Cardiol"},{"key":"441_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1342409","author":"VF Panoulas","year":"2024","unstructured":"Panoulas VF, Escaned J, Hill JM, et al. Predictors of left ventricular ejection fraction in high-risk percutaneous coronary interventions. Front Cardiovasc Med. 2024. https:\/\/doi.org\/10.3389\/fcvm.2024.1342409.","journal-title":"Front Cardiovasc Med"},{"key":"441_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1416613","author":"S Farhan","year":"2024","unstructured":"Farhan S, Freilich M, Giustino G, et al. Change in left ventricular function and outcomes following high-risk percutaneous coronary intervention with Impella-guided hemodynamic support. Front Cardiovasc Med. 2024. https:\/\/doi.org\/10.3389\/fcvm.2024.1416613.","journal-title":"Front Cardiovasc Med"},{"key":"441_CR36","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ahj.2016.05.003","volume":"178","author":"NR Sutton","year":"2016","unstructured":"Sutton NR, Li S, Thomas L, et al. The association of left ventricular ejection fraction with clinical outcomes after myocardial infarction: findings from the Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get with the Guidelines (GWTG) Medicare-linked database. Am Heart J. 2016;178:65\u201373. https:\/\/doi.org\/10.1016\/j.ahj.2016.05.003.","journal-title":"Am Heart J"},{"key":"441_CR37","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.035791","author":"G Ndrepepa","year":"2024","unstructured":"Ndrepepa G, Cassese S, Byrne RA, et al. Left ventricular ejection fraction change following percutaneous coronary intervention: correlates and association with prognosis. J Am Heart Assoc. 2024. https:\/\/doi.org\/10.1161\/JAHA.124.035791.","journal-title":"J Am Heart Assoc"},{"key":"441_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.856870","author":"A Attinger-Toller","year":"2022","unstructured":"Attinger-Toller A, Bossard M, Cioffi GM, et al. Ventricular unloading using the Impella\u2122 device in cardiogenic shock. Front Cardiovasc Med. 2022. https:\/\/doi.org\/10.3389\/fcvm.2022.856870.","journal-title":"Front Cardiovasc Med"},{"key":"441_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd10040140","author":"B De Lazzari","year":"2023","unstructured":"De Lazzari B, Capoccia M, Badagliacca R, Bozkurt S, De Lazzari C. IABP versus Impella support in cardiogenic shock: \u201cin silico\u201d study. J Cardiovasc Dev Dis. 2023. https:\/\/doi.org\/10.3390\/jcdd10040140.","journal-title":"J Cardiovasc Dev Dis"},{"key":"441_CR40","doi-asserted-by":"publisher","unstructured":"Myat A, Patel N, Tehrani S, Banning AP, Redwood SR, Bhatt DL. Percutaneous circulatory assist devices for high-risk coronary intervention. JACC Cardiovasc Interv. 2015. https:\/\/doi.org\/10.1016\/j.jcin.2014.07.030.","DOI":"10.1016\/j.jcin.2014.07.030"},{"key":"441_CR41","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10286-024-01086-5","volume":"35","author":"T Warnakulasuriya","year":"2025","unstructured":"Warnakulasuriya T, George B, Lever N, Ramchandra R. Mechanical circulatory support reduces renal sympathetic nerve activity in an ovine model of acute myocardial infarction. Clin Auton Res. 2025;35:193\u2013203. https:\/\/doi.org\/10.1007\/s10286-024-01086-5.","journal-title":"Clin Auton Res"},{"key":"441_CR42","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.058229","author":"E L\u00fcsebrink","year":"2022","unstructured":"L\u00fcsebrink E, Kellnar A, Krieg K, et al. Percutaneous transvalvular microaxial flow pump support in cardiology. Circulation. 2022. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.058229.","journal-title":"Circulation"},{"key":"441_CR43","doi-asserted-by":"crossref","unstructured":"Vetrovec GW, Kaki A, Dahle TG. A review of bleeding risk with impella-supported high-risk percutaneous coronary intervention. Heart Int. 2020;14(2):92\u201399.","DOI":"10.17925\/HI.2020.14.2.92"},{"key":"441_CR44","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1161\/CIRCULATIONAHA.119.044007","volume":"141","author":"AP Amin","year":"2020","unstructured":"Amin AP, Spertus JA, Curtis JP, et al. The evolving landscape of impella use in the united states among patients undergoing percutaneous coronary intervention with mechanical circulatory support. Circulation. 2020;141:273\u201384. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044007.","journal-title":"Circulation"},{"key":"441_CR45","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.123.013367","volume":"17","author":"M Ryan","year":"2024","unstructured":"Ryan M, Ezad SM, Webb I, et al. Percutaneous left ventricular unloading during high-risk coronary intervention: rationale and design of the CHIP-BCIS3 randomized controlled trial. Circ Cardiovasc Interv. 2024;17:E013367. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.123.013367.","journal-title":"Circ Cardiovasc Interv"},{"key":"441_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2024.06.016","author":"K Hirai","year":"2024","unstructured":"Hirai K, Kawasaki T, Kishi K, et al. Determinants of one-year outcome after successful percutaneous coronary intervention for chronic total occlusion; insight from Japanese CTO-PCI expert registry. Am J Cardiol. 2024. https:\/\/doi.org\/10.1016\/j.amjcard.2024.06.016.","journal-title":"Am J Cardiol"},{"key":"441_CR47","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.037424","author":"PE Miller","year":"2025","unstructured":"Miller PE, Gordon AS, Liu Y, et al. Mechanical circulatory support in patients without cardiogenic shock undergoing percutaneous coronary intervention. J Am Heart Assoc. 2025. https:\/\/doi.org\/10.1161\/JAHA.124.037424.","journal-title":"J Am Heart Assoc"},{"key":"441_CR48","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1001\/jama.2020.0254","volume":"323","author":"SS Dhruva","year":"2020","unstructured":"Dhruva SS, Ross JS, Mortazavi BJ, et al. Association of use of an intravascular microaxial left ventricular assist device vs intra-aortic balloon pump with in-hospital mortality and major bleeding among patients with acute myocardial infarction complicated by cardiogenic shock. JAMA. 2020;323:734\u201345. https:\/\/doi.org\/10.1001\/jama.2020.0254.","journal-title":"JAMA"},{"key":"441_CR49","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jjcc.2024.09.009","volume":"85","author":"M Yokoi","year":"2025","unstructured":"Yokoi M, Ito T, Shintani Y, et al. Clinical characteristics and short-term outcomes in patients with cardiogenic shock undergoing mechanical circulatory support escalation from intra-aortic balloon pump to impella: from the J-PVAD registry. J Cardiol. 2025;85:337\u201342. https:\/\/doi.org\/10.1016\/j.jjcc.2024.09.009.","journal-title":"J Cardiol"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-025-00441-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-025-00441-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-025-00441-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T17:26:27Z","timestamp":1773509187000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-025-00441-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,13]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["441"],"URL":"https:\/\/doi.org\/10.1007\/s40119-025-00441-5","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,13]]},"assertion":[{"value":"18 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jason R. Wollmuth reports speaking and consulting honoraria from Johnson & Johnson\/Abiomed, Abbott Vascular, Boston Scientific, and Shockwave Medical. Aditya S. Bharadwaj reports speaking and consulting honoraria from Johnson & Johnson\/Abiomed, Shockwave Medical, and Abbott CSI. Nudrat Noor and Ali Almedhychy are employees of Johnson & Johnson MedTech. William O\u2019Neill reports consultancy and research support from Johnson & Johnson, Edwards Lifesciences, Boston Scientific, Abbott, and Zoll.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This observational cohort study used only de-identified patient records obtained from the Truveta electronic health record platform. As such, it did not require institutional review board approval or informed consent, in accordance with the Common Rule and applicable US federal regulations. De-identification was verified through expert determination consistent with the Health Insurance Portability and Accountability Act Privacy Rule. The study was conducted in accordance with the principles of the Declaration of Helsinki (1964) and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}